Howard W. Robin, President & CEO at NEKTAR THERAPEUTICS (NKTR), sold 20,781 shares at $32.37 ($755K) on 2025-09-04, disclosed to the SEC on 2025-09-08.
Scheduled sale ($755k) by President & CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $32.37 | 1,923 | $62K | 8.2% |
| 2 | $32.37 | 1,923 | $62K | 8.2% |
| 3 | $33.54 | 1,496 | $50K | 6.6% |
| 4 | $33.54 | 1,496 | $50K | 6.6% |
| 5 | $34.40 | 613 | $21K | 2.8% |
| 6 | $35.80 | 1,134 |
| $41K |
| 5.4% |
| 7 | $37.87 | 3,304 | $125K | 16.6% |
| 8 | $37.87 | 3,304 | $125K | 16.6% |
| 9 | $38.82 | 2,226 | $86K | 11.4% |
| 10 | $38.82 | 2,226 | $86K | 11.4% |
| 11 | $39.89 | 1,136 | $45K | 6.0% |
| Total | $36.33 avg | 20,781 | $755K | 100% |
| Filing → |
| NKTR | SELL | 2026-05-21 | $29K | — | Filing → |
| NKTR | SELL | 2026-02-20 | $31K | — | Filing → |
| NKTR | SELL | 2025-11-25 | $240K | — | Filing → |